Evans is admired for his fearless leadership and tireless campaigning journalism.
Academic rigour, journalistic flair
Articles on Thalidomide
Displaying 1 - 20 of 25 articles
The infamous drug can inhibit the body's inflammatory response, which is why researchers wonder if it can effectively treat COVID-19.
As the measles outbreaks spread, public health officials are trying different measures to curb it. Yet there are limits to what they can do as they balance community safety and personal freedom.
A new book, 'The Thalidomide Catastrophe,' raises new questions about the conduct of corporations involved. It is the duty of governments to find out the answers.
Virtually every medical therapy in use today owes its existence to animal experiments. But we can't assume what works in animals will in humans. And sometimes, the mismatch can be dangerous.
We still don't know what's behind four out of every five birth defects. But that can change.
The randomised controlled trial is touted as the gold standard in medical research. But its controlled laboratory conditions are far removed from the messy realities of life.
The MHRA has opened an inquiry on the once popular pregnancy test pills. Did they really cause birth defects in children born in the 1970s?
This was the year of the health review – mental health care, Medicare, private health insurance, the pharmacy industry ... and the list goes on. But how much movement was there on policy?
Thalidomide is notorious for causing death and disability but it – and its derivatives – are proving useful for conditions such as leprosy.
The thalidomide tragedy changed how medicines are viewed during pregnancy – not only by pregnant women, but also the wider community.
Tighter regulations of medicines and devices have prevented countless deaths and disabilities. But regulation can't always protect us from harm.
Thalidomide was responsible for one of the biggest drug disasters in history. It is making a comeback. But is Africa equipped to handle this controversial drug?
Reactions to the thalidomiders' difference contributed – and continue to contribute – to their negative well-being and deteriorating health.
Decades have passed and yet the issue of financial compensation for the remaining "survivors" of the thalidomide tragedy has, in many instances, remained unresolved.
Journalist-turned-lawyer Michael Magazanik worked on recent Australian thalidomide lawsuits. As part of our series on the drug, he spoke to Ian Freckelton about the book he wrote, based on the case.
Thalidomide's manufacturer, Chemie Grünenthal, marketed the drug as safe for pregnant women despite reports it was causing malformations in newborns. Why such blatant denial?
Sir Harold Evans talks to Richard Sambrook about The Sunday Times' moral campaign against thalidomide's manufacturers, the fight for political validation and the rise of investigative journalism.
Thalidomide was developed in an era of widespread enthusiasm – but little critical attention – for pharmaceutical therapies.
Thalidomide was marketed as a safe, sleep-inducing drug, but when taken during pregnancy it could cause severe birth defects.
Job Board
-
UniSA Connect Outreach Scholarship
-
POSTDOCTORAL RESEARCH FELLOW IN META-OPTICAL DEVICES
-
Lecturer, ECDF in Nursing
-
Commissioning Editor - Business & Economy Desk
-
Project Assistant
Top contributors
-
Senior Lecturer in Pharmacy, The University of Queensland
-
Professor in Developmental Biology, University of Aberdeen
-
Associate Professor of History, University of Wollongong
-
Senior Research Fellow, Bioethics, University of Sydney
-
Adjunct Fellow, School of Law & School of Medicine, Western Sydney University
-
Lecturer in History of Medicine/Life Science, University of Melbourne
-
Associate Professor, Cumming School of Medicine, University of Calgary
-
Head, Cancer Research Program, Monash University
-
Professor of Journalism, Director of the Centre for Journalism, Cardiff University
-
Epidemiologist, University of Melbourne
-
Professorial Fellow in Law, University of Melbourne
-
Honorary Professor in History, University of KwaZulu-Natal
-
Director, Lemelson Center for the Study of Invention and Innovation, Smithsonian Institution
-
Assistant Professor, Sociology, University of Victoria
-
Manager, Cancer Research Program, Monash University
